Clinical
Osimertinib Plus Platinum-based Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Post-progression on First-Line Osimertinib: ORCHARD
Summary
The phase II ORCHARD platform study evaluated the efficacy and safety of osimertinib combined with carboplatin and pemetrexed in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who progressed on first-line osimertinib monotherapy. Among 31 treated patients, the confirmed objective response rate was 26%, with a median duration of response of 7.6 months. Median progression-free survival reached 5.6 months, while median overall survival was 10.9 months. Grade ≥ 3 adverse events occurred in 65% of patients, leading to treatment discontinuation in 23%. These findings suggest that continuing osimertinib alongside platinum-based doublet chemotherapy offers modest clinical benefit post-progression.
Critical appraisal
This report provides phase II non-comparative evidence from a platform trial evaluating the strategy of continuing osimertinib beyond progression in combination with platinum-pemetrexed chemotherapy. Reported efficacy metrics indicate modest activity in an unselected post-osimertinib cohort, showing an ORR of 26% (80% CI: 16-39), a median PFS of 5.6 months, and a median OS of 10.9 months. Grade ≥ 3 adverse events were observed in 65% of patients, prompting treatment discontinuation in 23%. Given contemporary practice changes—including frontline combination regimens (FLAURA2) and amivantamab-based combinations in the post-progression setting (MARIPOSA-2)—this regimen has limited potential to alter clinical practice guidelines, serving primarily as an accessible pragmatic alternative within the next 1–3 years where novel targeted options are unavailable.
The summary and the appraisal were written by a language model from the title and abstract of the original article. The article was selected automatically by a model, without human review. Methodology